Genvec Inc (GNVC) 0.53 $GNVC GenVec Reports Second

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genvec Inc (GNVC) 0.53 $GNVC

GenVec Reports Second Quarter 2016 Financial Results
PR Newswire - Fri Aug 05, 6:30AM CDT
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the second quarter ended June 30, 2016. For the three months ended June 30, 2016, the company reported a net loss of $1.2 million or $0.06 per share on revenues of $26,000. This compares to a net loss of $1.9 million or $0.11 per share on revenues of $127,000 for the same period in the prior year. For the six months ended June 30, 2016, the company reported a net loss of $3.1 million or $0.16 per share on revenues of $0.3 million. This compares to a net loss of $3.4 million or $0.21 per share on revenues of $0.5 million for the same period in the prior year. The company ended the second quarter of 2016 with $9.6 million in cash and cash equivalents.
GNVC: 0.53 (-0.04)

Can DENTSPLY (XRAY) Spring an Earnings Surprise in Q2?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:15AM CDT
DENTSPLY SIRONA Inc. (XRAY) is expected to report second-quarter 2016 results on Aug 5.
GNVC: 0.53 (-0.04), ANIP: 59.74 (-1.12), XRAY: 61.46 (-0.04), COO: 185.92 (-0.46)

GenVec Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 12, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the first quarter ended March 31, 2016. For the three months ended March 31, 2016, the company reported a net loss of $1.9 million, or $0.11 per share, compared with a net loss of $1.5 million, or $0.09 per share, for the three months ended March 31, 2015. The company ended the first quarter with $6.9 million in cash, cash equivalents, and liquid investments.
GNVC: 0.53 (-0.04)

GenVec Provides Update on Hearing Loss Clinical Program
PR Newswire - Mon May 02, 6:00AM CDT
GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, announced today that it was notified by its collaborator Novartis that the Data Safety Monitoring Board (DSMB) for the Phase 1/2 clinical trial of CGF166 in patients with severe to profound hearing loss has recommended that the trial continue, subject to approval by the U.S. Food and Drug Administration (FDA). This recommendation was based on a review of safety and efficacy data from the nine patients currently enrolled in the study. Novartis is developing CGF166, GenVec's lead product candidate for hearing loss, under a Research Collaboration and License Agreement with GenVec. As previously disclosed, on January 8, 2016, GenVec was notified by Novartis that enrollment was paused in the clinical study for CGF166 in accordance with criteria in the trial protocol.
GNVC: 0.53 (-0.04), NVS: 78.77 (-0.57)

GenVec Provides Investor Update
PR Newswire - Wed Jan 20, 6:00AM CST
GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, provided an update to investors on recent developments and the company's strategic focus.
GNVC: 0.53 (-0.04), NVS: 78.77 (-0.57)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of GenVec, Inc. (GNVC)
PR Newswire - Mon Jan 11, 11:56AM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of GenVec, Inc. ("GenVec" or the "Company" (Nasdaq: GNVC). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
GNVC: 0.53 (-0.04)

GenVec Receives Notice of Allowance for Patent Application Providing Broad Protection of Its Gorilla Adenovectors
PR Newswire - Wed Dec 02, 7:00AM CST
GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, announced today that it received a notice of allowance for its patent application entitled "Affenadenovirus (Gorilla) or Adenoviral Vectors and Methods of Use" from the U.S. Patent and Trademark Office. The allowed claims cover composition of matter for the company's proprietary adenovectors isolated from mountain gorillas, including potential adjustments and additions that may be introduced to engineer these vectors for optimal suitability and performance in a variety of therapeutic and vaccine applications. One key advantage of our approach is that most people do not have pre-existing immunity to gorilla vectors. Such pre-existing immunity can interfere with vectors derived from more commonly encountered viruses and viral serotypes.
GNVC: 0.53 (-0.04)

GenVec Reports Third Quarter 2015 Financial Results
PR Newswire - Mon Nov 09, 7:00AM CST
GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, reported financial results for the third quarter ended September 30, 2015. For the three months ended September 30, 2015, GenVec reported a net loss of $1.5 million, or $0.09 per share, on revenues of $0.2 million, compared with a net loss of $1.6 million, or $0.10 per share, on revenues of $0.3 million, for the same period in the prior year. For the nine months ended September 30, 2015, GenVec reported a net loss of $4.9 million, or $0.30 per share, on revenues of $0.7 million, compared with a net loss of $4.2 million, or $0.27 per share, on revenues of $2.5 million, for the same period in the prior year. GenVec ended the third quarter of 2015 with $9.9 million in cash, cash equivalents and investments.
GNVC: 0.53 (-0.04)

GenVec Expands I.P. Portfolio With Issuance Of U.S. And European Patents For Monkey Adenoviral Vectors
PR Newswire - Mon Sep 28, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced that on September 15, 2015, the U.S. Patent and Trademark Office issued patent 9133248, covering methods of propagating proprietary gene delivery adenovectors isolated from new and old world monkeys. This patent complements European Patent No. 2498791, "Methods of Propagating Monkey Adenoviral Vectors". Patent applications in this family are also pending in Japan, China, India and Canada as well as other inventive claims in divisional applications. GenVec's monkey adenovectors provide additional, complementary features to our already broad platform providing greater flexibility to efficiently address a wide variety of gene delivery applications. In addition, GenVec's entire portfolio of vectors grow to high yields in our proprietary cell lines and can be readily manufactured under GMP conditions making them strong candidates for therapeutic use.
GNVC: 0.53 (-0.04)

GenVec (GNVC) Shows Strength: Stock Moves Up 18.7%
Zacks Equity Research - Zacks Investment Research - Mon Sep 21, 7:51AM CDT
GenVec, Inc. (GNVC) was a big mover last session, as its shares rose almost 19% on the day.
GNVC: 0.53 (-0.04), GILD: 78.38 (+0.46)

GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines
PR Newswire - Wed Jun 03, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced a multi-faceted collaboration with Dr. David T. Curiel and his team from the School of Medicine at Washington University at St. Louis (WUSTL). Dr. Curiel is the director of the Biologic Therapeutic Center and the Cancer Biology Division within the Department of Radiation Oncology.
GNVC: 0.53 (-0.04)

GenVec Highlights Proprietary Gorilla Vectors At ASGCT Presentation
PR Newswire - Thu May 14, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) announced today that Douglas E. Brough, the company's chief scientific officer, gave a presentation entitled "Gorilla Adenovirus Vectors for Molecular Therapeutics and Vaccines" at the 18th Annual Meeting of the American Society of Gene & Cell Therapy. The presentation highlighted the results of preclinical research conducted using the company's propriety adenovirus vectors originally isolated from mountain gorillas. These adenovectors have demonstrated superior performance to induce high level durable antigen specific antibody and T cell responses in GenVec's preclinical models for respiratory syncytial virus, herpes simplex virus, and malaria from a single administration. GenVec is working to test these 'gorilla Ads' in a variety of configurations through research conducted by its own laboratories and through collaborations and partnerships.
GNVC: 0.53 (-0.04)

Michael Richman Appointed To GenVec Board Of Directors
PR Newswire - Wed Apr 22, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced that the Board of Directors of GenVec, Inc. appointed Michael Richman as a director of the company.
GNVC: 0.53 (-0.04)

GenVec Announces Collaboration with the Laboratory of Malaria Immunology & Vaccinology
PR Newswire - Tue Apr 21, 7:01AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced that it has signed a research collaboration agreement with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.
GNVC: 0.53 (-0.04)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 58

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 42

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 174

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 15

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 203

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 52

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 22

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 15

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 282

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 113

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading

Top 5 Most Recently Viewed Articles

BIEL Crystal's Innovative Smartphone Glass Cover Revolutionizes Durability

Updated Category News Views 299

BIEL Crystal's Innovative Smartphone Glass Cover BIEL Crystal, a notable supplier for Apple and a leader in smart device components, has recently introduced its cutting-edge product, the "Witch Cloak." This ultra-hard coating smartphone glass cover represents a significant advancement in the technology used to protect smartphones from daily wear and tear, notably featured...

Continue Reading
Covenant Clearinghouse Triumphs in Legal Battle with Chicago Title

Updated Category News Views 780

Covenant Clearinghouse Triumphs in Legal Battle Covenant Clearinghouse recently achieved a significant legal victory against the Chicago Title Company, concluding a complex litigation case. The case, documented as Chicago Title Ins. Co. v. Covenant Clearinghouse, LLC, revolved around crucial property rights under the Illinois Transfer Fee Covenant Act. Legal Proceedings...

Continue Reading
TTEC CEO's Buyout Proposal: What It Means for Stakeholders

Updated Category News Views 137

TTEC's CEO Buyout Proposal: Evaluating the Future TTEC Holdings, Inc. (NASDAQ: TTEC), known for its AI-driven customer experience solutions, is currently assessing a buyout proposal presented by its CEO, Kenneth Tuchman. This significant move has prompted the company to engage the services of Rothschild & Co as its financial advisor, alongside legal support from Skadden,...

Continue Reading
Primech AI Unveils HYTRON LITE Bathroom Cleaning Solution

Updated Category News Views 167

Primech AI Launches Innovative HYTRON LITE at Industry Event Primech AI Pte. Ltd. (Nasdaq: PMEC) is making waves in the robotics industry with its latest innovative creation, the HYTRON LITE bathroom cleaning robot, introduced during a significant event focused on facilities management. This gathering, that united key players, took place at Temasek Polytechnic and was...

Continue Reading
The Growth Journey of Travelers Companies: A Five-Year Analysis

Updated Category News Views 255

Understanding Travelers Companies' Market Performance When evaluating the potential return on investment in stocks, it's essential to look at the historical performance of companies like Travelers Companies (NYSE: TRV). This prominent insurance provider has shown remarkable consistency and growth over the years, recently achieving a market capitalization of $63.96...

Continue Reading